BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...to treat chronic constipation AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) / Antares Pharma Inc. (NASDAQ:ATRS) FDA approves subcutaneous Makena...
BioCentury | Feb 16, 2018
Clinical News

FDA approves AMAG's new Makena formulation

...FDA approved an sNDA from AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) for subcutaneous Makena hydroxyprogesterone caproate injection to reduce...
...in women who spontaneously delivered one preterm baby in the past. AMAG plans to launch subcutaneous Makena...
...Waltham, Mass. Antares Pharma Inc. (NASDAQ:ATRS), Ewing, N.J. Product: Subcutaneous Makena hydroxyprogesterone caproate injection Business: Genitourinary Allison Johnson subcutaneous Makena AMAG...
BioCentury | Feb 15, 2018
Company News

AMAG gets second FDA approval in two weeks

...FDA approved an sNDA from AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) for subcutaneous Makena hydroxyprogesterone caproate injection to reduce...
...Pharma Inc. (NASDAQ:ATRS) added $0.37 (19%) to $2.35 on the news. AMAG plans to launch subcutaneous Makena...
...already marketed in the U.S. to treat IDA in adults with chronic kidney disease (CKD). Allison Johnson Feraheme Makena subcutaneous Makena AMAG...
BioCentury | May 3, 2017
Clinical News

AMAG submits sNDA for subcutaneous Makena

...AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) submitted an sNDA to FDA for subcutaneous Makena hydroxyprogesterone caproate injection to reduce...
...Inc. (NASDAQ:AMAG), Waltham, Mass. Product: Subcutaneous Makena hydroxyprogesterone caproate injection Business: Genitourinary Alicia Parker hydroxyprogesterone caproate injection Makena AMAG Pharmaceuticals Inc. Subcutaneous Makena...
Items per page:
1 - 4 of 4